GLP1R and type 2 diabetes mellitus: Expanding on our previous large network meta-analysis2that focused on SGLT-2 inhibitors and GLP-1 receptor agonists, this synthesis of the best current evidence on clinically relevant benefits and harms of all available drugs for people with type 2 diabetes included finerenone and tirzepatide, which are new to clinicians.